VK2735 oral
VK2735 · Viking Therapeutics
Once-daily oral GLP-1/GIP agonist; the Phase 3 SUNRISE program began in October 2026.
Selected study results
VENTURE · tabletMean body-weight reductionBody weight decreased 12.2% · 13 weeks · Phase 2
Mean body-weight reduction · 13 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity or overweight and a weight-related complication, without diabetes · 120 mg once daily after escalation vs placebo · Trial N=280 · Least-squares means; efficacy population; mixed model. Results & methods ↗
Only 7 weeks were spent at 120 mg. Oral and injectable milligram strengths are not equivalent.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: SUNRISE-1 and SUNRISE-2 are recruiting per November 16, 2026 registry postings, following Viking’s October 14 program-initiation announcement. Separate VENTURE oral Phase 2 results remain the current efficacy evidence.
Next: SUNRISE Phase 3 outcomes. The separate exploratory maintenance study began Part 2 in October 2026; it evaluates daily oral, monthly subcutaneous, or every-other-week subcutaneous maintenance after weekly injections, with results expected in 2027.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
SUNRISE-1
Weight management without type 2 diabetesAdults with obesity or overweight and a weight-related comorbidity, without type 2 diabetes; randomized, double-blind, placebo-controlled 68-week daily oral study. Estimated enrollment 560 in this protocol; primary endpoint is percent body-weight change at week 68. Recruiting per November 16 registry posting. The registry still labels the November 2026 start date as estimated; no Phase 3 results are posted.
SUNRISE-2
Weight management with type 2 diabetesAdults with obesity or overweight and a weight-related comorbidity, with type 2 diabetes; randomized, double-blind, placebo-controlled 68-week daily oral study. Estimated enrollment 560 in this protocol; primary endpoint is percent body-weight change at week 68. Recruiting per November 16 registry posting. The registry still labels the November 2026 start date as estimated; no Phase 3 results are posted.
Phase 2 studies1 record
VENTURE · oral
Weight management13-week obesity study; only seven weeks at the highest dose.
